This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the rollout opportunities for YORVIPATH (palopegteriparatide), recently approved by the FDA for the treatment of hypoparathyroidism in adults.
Ticker(s): ASNDWho's the expert?
Institution: Stanford University
Board-certified endocrinologist serving as clinical assistant professor at Stanford University, specializing in thyroid, parathyroid, adrenal, and pituitary gland disorders.
Collaborates with cancer specialists to manage endocrine side effects of immunotherapy, developing personalized care plans for optimal patient outcomes.
Program Director for Stanford’s Endocrinology Fellowship, contributing to medical education and authoring research on hypopituitarism and thyroid disease.
Interview GoalThis call will discuss the current treatment landscape and the potential of YORVIPATH (palopegteriparatide), recently approved by the FDA for the treatment of hypoparathyroidism in adults along with its pre-approval data.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
